Abstract
Aim. To develop a computer program to determine the probability of colorectal cancer based on the assessment of the levels of CTLA-4 and its ligand B7.2.Materials and methods. The study included 44 patients with colorectal cancer (CRC) and 25 patients with benign tumors of the colon. The control group consisted of 25 individuals who had been operated for colon injury. We determined the levels of CTLA-4 and B7.2 in the blood serum and in the supernatants of tumor tissue and lymph node homogenates using flow cytofluorometry.Results. We found that the level of CTLA-4 in the blood serum increased by 2.77 times in CRC patients compared to the control group (p < 0.001). The concentration of CTLA-4 in the tumor tissue in patients with CRC was 2.34 times higher than in the control group (p = 0.007). The concentration of the B7.2 ligand in the blood serum of patients with CRC exceeded this parameter in the control group by 2.51 times (p = 0.002). The concentration of B7.2 in the tumor tissue of CRC patients was 1.68 times higher (p = 0.004) than in the control group. The analysis of the obtained data determined the parameters that have prognostic value in the structure of the diagnostic model. Using these parameters, we developed a computer program to determine the probability of CRC in the patient.Conclusion. The data obtained demonstrate an increase in the levels of CTLA-4 and its ligand B7.2 in the serum and tumor tissue of patients with CRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
